Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Opgen Inc (NQ: OPGN )

1.360 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Opgen Inc

OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From OpGen, Inc.
Via Globe NewsWire
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
From OpGen, Inc.
Via Globe NewsWire
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth
From OpGen, Inc.
Via Globe NewsWire
OpGen Announces Exercise of All Prefunded Warrants
From OpGen, Inc.
Via Globe NewsWire
OpGen subsidiary Ares Genetics announces granting of key patent in China
From OpGen, Inc.
Via Globe NewsWire
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
From OpGen, Inc.
Via Globe NewsWire
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
Successful delivery of milestones triggers milestone payment 
From OpGen, Inc.
Via Globe NewsWire
OpGen Announces Closing of $7.5 Million Public Offering
From OpGen, Inc.
Via Globe NewsWire
OpGen Announces Pricing of $7.5 Million Public Offering
From OpGen, Inc.
Via Globe NewsWire
OpGen Announced 1-for-20 Reverse Stock Split
From OpGen, Inc.
Via Globe NewsWire
OpGen (NASDAQ: OPGN) Reports Positive Data from Clinical Trial for Unyvero as Diagnostic for UTI
OpGen, Inc. (NASDAQ: OPGN) is engaged as a precision medicine company that is focused on developing molecular diagnostics and bioinformatics 
Via Spotlight Growth
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
From OpGen, Inc.
Via Globe NewsWire
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
From OpGen, Inc.
Via Globe NewsWire
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update
From OpGen, Inc.
Via Globe NewsWire
OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time
From OpGen, Inc.
Via Globe NewsWire
OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support
From OpGen, Inc.
Via Globe NewsWire
OpGen Announces Closing of $3.38 Million Registered Direct Offering
From OpGen, Inc.
Via Globe NewsWire
OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel
From OpGen, Inc.
Via Globe NewsWire
OpGen Announces $3.38 Million Registered Direct Offering
From OpGen, Inc.
Via Globe NewsWire
OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven
From OpGen, Inc.
Via Globe NewsWire
OpGen, Inc. (NASDAQ:OPGN) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 02/15/2022 -- Certain directors of OpGen, Inc are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Investigation Announced for Investors in OpGen, Inc. (NASDAQ:OPGN) Shares
San Diego, CA -- (SBWIRE) -- 12/15/2021 -- An investigation was announced for investors of OpGen, Inc. (NASDAQ:OPGN) shares over potential securities laws violations by OpGen, Inc. 
Via SBWire
NASDAQ: OPGN Investor Notice: Investigation over Potential Wrongdoing at OpGen, Inc.
San Diego, CA -- (SBWIRE) -- 11/30/2021 -- An investigation on behalf of investors in OpGen, Inc. (NASDAQ: OPGN) shares over potential wrongdoing at OpGen, Inc. was announced. 
Via SBWire
OpGen, Inc. (NASDAQ:OPGN) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 11/10/2021 -- OpGen, Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.